Phase 2 Study of Radiotherapy Followed by Durvalumab and Ceralasertib for Stage III Non-Small Cell Lung Cancer with Thoracic Relapses and Limited Metastases After PACIFIC Treatment
Led by Mario Negri Institute for Pharmacological Research · Updated on 2025-12-18
21
Participants Needed
9
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of thoracic re-irradiation with or without stereotactic body radiotherapy SBRT followed by treatment with durvalumab and ceralasertib in patients with stage III non-small cell lung cancer NSCLC who have thoracic relapses, with or without limited metastatic disease. This phase 2 study focuses on patients who previously received PACIFIC or similar chemo-radiotherapy regimens followed by durvalumab maintenance. The goal is to explore new treatment approaches for patients experiencing disease recurrence after initial therapy.
The study treatment begins with radiotherapy targeting local tumor recurrences and regional lymph node metastases with doses ranging from 36 to 50 Gy in daily fractions. Two weeks after completing radiotherapy, participants will start systemic therapy with durvalumab administered by intravenous infusion every four weeks and oral ceralasertib given twice daily for one week in each 28-day cycle. Treatment continues until disease progression, unacceptable side effects, or withdrawal from the study.
Participants will undergo regular assessments including imaging scans CT, PET, brain MRI, tumor measurements, and monitoring for side effects. Researchers will evaluate safety by tracking severe treatment-related adverse events over six months and measure progression-free survival at 12 months as the primary outcome. Secondary outcomes include response rates and overall survival at 6 and 12 months. The study requires participants to comply with scheduled visits and follow-up procedures throughout the treatment period.
CONDITIONS
Brief Title
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Research Team
I
Irene De Simone, Project manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Mario Negri Institute for Pharmacological Research
Lead Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Signed, written, and dated informed consent
Male or female aged 18 years or older
ECOG Performance Status of 0-2
Life expectancy of at least 6 months at treatment start
Body weight over 30 kg
Maintenance treatment with durvalumab for at least 3 months
Histologically or cytologically confirmed locally advanced NSCLC at relapse
Measurable disease per RECIST v1.1
Documented tumor PD-L1 status at diagnosis or relapse
Thoracic progression as defined by PACIFIC protocol with up to 3 metastatic lesions suitable for radiotherapy
Interval of more than 12 months since end of first thoracic radiotherapy
Pre-treatment whole body CT scan with contrast
Pre-treatment CT-PET scan
Pre-treatment brain MRI
Evidence of post-menopausal status or negative pregnancy test for pre-menopausal females
Willing and able to comply with study procedures including treatment and visits
You will not qualify if you...
Discontinued durvalumab due to progression during maintenance phase less than 12 months after chemoradiotherapy
Experienced grade 3 or higher immune-related toxicity or radiation pneumonitis during durvalumab maintenance
Unresolved toxicities from prior cancer therapy except alopecia, vitiligo, or specified lab values
Toxicity causing permanent discontinuation of prior immunotherapy
More than 3 distant metastases (non-oligometastatic disease)
Metastatic disease not suitable for radical radiotherapy (e.g., malignant effusions, diffuse lymphangiosis, bone marrow metastasis, GI tract invasion)
Major surgery within 28 days before first study drug dose (except local palliative surgery)
Diagnosis of ataxia telangiectasia
Presence of targetable genomic alterations such as EGFR, HER-2, MET exon 14 skipping, ALK, ROS1, RET, or NTRK rearrangements
Uncontrolled illness including active infection, heart failure, hypertension, angina, arrhythmia, interstitial lung disease, serious GI conditions, or psychiatric/social issues limiting compliance
Participation in another interventional clinical study within last 4 weeks
Concurrent chemotherapy, immunotherapy, biological or hormonal cancer therapy (except non-cancer hormonal therapy)
Inadequate bone marrow or organ function per specified lab criteria
History of active primary immunodeficiency
Active or prior autoimmune or inflammatory disorders except specified exceptions
Pregnant or breastfeeding females, or patients not using effective birth control
History of allogenic organ transplantation
Any condition interfering with study drug evaluation or patient safety per investigator judgment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Radiotherapy
Duration - Until completion of radiotherapy fractions
Participants receive radiotherapy targeting loco-regional recurrences of the primary tumor and regional lymph node metastases.
Daily visits for radiotherapy sessions
Treatment
Duration - Repeated 28-day cycles until disease progression or discontinuation
Two weeks after radiotherapy, participants receive durvalumab via IV infusion every 4 weeks and oral ceralasertib twice daily on days 1 to 7 of each 28-day cycle until disease progression or unacceptable toxicity.
1 infusion visit every 4 weeks and daily oral medication for 7 days each cycle
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study of Nivolumab Plus Chemotherapy Before Surgery in Patients with Resectable Non-Small Cell Lung Cancer in Taiwan
Observational Study of Amivantamab and Chemotherapy in Adults with Metastatic Non-Small Cell Lung Cancer with EGFR Mutations
Phase IbII Study of Vebreltinib and Furmonertinib Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer with c-Met Amplification After EGFR-TKI Therapy Failure
Phase 2 Study of Radiotherapy Followed by Durvalumab and Ceralasertib for Stage III Non-Small Cell Lung Cancer with Thoracic Relapses and Limited Metastases After PACIFIC Treatment
Evaluating DNA and RNA from Extracellular Vesicles in Bronchial Lavage for Genetic Testing
in Advanced Non-Small Cell Lung Cancer Patients
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.
Andrea Riccardo Filippi, Eliana Rulli, Diego Signorelli...